Skip to main content

Table 1 Demographic data of patients

From: Accelerated activation of the coagulation pathway during cardiopulmonary bypass in aortic replacement surgery: a prospective observational study

 

Aortic Replacement Group (n =14)

Valve Replacement Group (n = 14)

p value

Age (years)

68.4 ± 6.5

70.8 ± 7.3

0.1809

Sex (M/F)

9/5

10/4

 

Height (cm)

164.3 ± 10.6

158.9 ± 10.3

0.0946

Weight (kg)

64.8 ± 16.8

57.6 ± 11.3

0.0961

BSA (m2)

1.70 ± 0.24

1.59 ± 0.19

0.0892

Cases

Ascending Aorta Replacement + AVR

2

MVP

1

 

AVR

2

 

Descending Aorta Replacement + CABG

1

AVR + TAP

1

 
 

Descending Aorta Replacement

2

AVR + MVP

2

 
 

TAR + AVR

1

AVR + MVP + CABG

1

 
 

TAR + CABG

3

AVR + MVR + TAP

1

 
 

TAR

4

AVR + CABG

5

 
 

Ascending Aorta Replacement + AVR + CABG

1

MVR + TAP

1

 

Fibrinogen (mg/dL)

339 (274–386)

314 (287–356)

0.4762

TAT (ng/mL)

7.7 (4–14.4)

2.1 (1.2–3.2)

0.0009*

SFMC (μg/mL)

20.8 (4.1–109.2)

3.9 (2.4–4.8)

0.0038*

FVIIa (mU/mL)

35.0 (26.3–42.3)

29.5 (21.3–34.8)

0.4616

Hemoglobin (g/dL)

11.6 (10.5–12.9)

11.1 (10.1–13.2)

0.5812

Platelet (×103/mL)

168 (138–194)

169 (133–190)

0.7304

PT-INR

1.17 (1.11–1.24)

1.17 (1.14–1.21)

0.9084

APTT (s)

33.6 (29.8–35.1)

34.0 (29.9–37.0)

0.6458

  1. AVR aortic valve replacement, MVP mitral valve plasty, MVR mitral valve replacement
  2. TAP tricuspid annuloplasty, CABG coronary artery bypass grafting, TAR total arch replacement
  3. *Significant difference between the two groups